Local NewsBusiness U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel), a New CAR T Cell Therapy for Adults with Relapsed or Refractory Large B-cell Lymphoma By Digital AIM Web Support - February 5, 2021 FacebookTwitterPinterestWhatsApp Like this:Like Loading... Related Featured Local Savings Featured Local Savings